© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90626 refers to an inactivated vaccine specifically designed to protect against the tick-borne encephalitis (TBE) virus. This vaccine is administered intramuscularly in a dosage of 0.25 mL. TBE is a serious viral infection that can lead to significant neurological complications, including muscle weakness, cognitive decline, and in severe cases, permanent paralysis or death. Unlike immune globulins, which offer only temporary, passive immunity, vaccines like this one provide active, long-lasting immunity. They work by introducing altered forms of the virus to the immune system, prompting it to produce its own antibodies. This process enables the body to "remember" how to respond to future exposures to the virus. The vaccine, TICOVAC™, which received approval in the U.S. in 2021, is effective in preventing TBE in both children and adults who are traveling to or living in areas where the virus is prevalent. While TBE is not currently endemic in the United States, it remains a significant health concern in various regions of Europe and Asia. It is important to note that when reporting this code, it is specifically for the vaccine product itself. The administration of the intramuscular injection should be reported separately, with the injection typically given in the arm for adults and in the thigh for children.
© Copyright 2025 Coding Ahead. All rights reserved.
The tick-borne encephalitis virus vaccine (CPT® Code 90626) is indicated for individuals who are at risk of exposure to the TBE virus. This includes:
The administration of the tick-borne encephalitis virus vaccine involves several key procedural steps:
Following the administration of the tick-borne encephalitis virus vaccine, patients may experience mild side effects, which can include soreness at the injection site, low-grade fever, or fatigue. These effects are generally short-lived and resolve without intervention. Patients should be advised to report any unusual or severe reactions to their healthcare provider. It is also important to inform patients about the need for follow-up doses if required, as per the vaccination schedule, to ensure optimal immunity against the TBE virus.
| Short Descr | TIC-BRN ENCEPH VAC 0.25ML IM | Medium Descr | TICK-BORNE ENCEPH VACC INACTIVATED 0.25ML IM USE | Long Descr | Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use | Status Code | Non-Covered Service | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2023-01-01 | Note | First appearance of the removal of the FDA approval icon in codebook. |
| 2022-07-01 | Note | FDA approval granted. |
| 2022-01-01 | Added | First appearance in codebook. |
| 2021-07-01 | Added | Code added. Effective upon receiving emergency Use Authorization or approval from the FDA. |
Get instant expert-level medical coding assistance.